DeepHealth Unveils Industry's Most Comprehensive Portfolio of Native Clinical AI Solutions at ECR 2026 

VIENNA, March 04, 2026 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today unveils at ECR 2026 the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities — MR, CT, X-ray, Mammography and Ultrasound — and spanning detection, assessment and monitoring, all available on one platform. With this week’s acquisition of Gleamer, DeepHealth further expands its leadership in advancing screening tools into routine imaging and acute diagnostic care, uniquely positioned to deliver the next era of AI-powered health informatics. 

"As European nations scale their screening ambitions and confront rising workload pressures, our integrated portfolio?is designed?to stage shift disease, empower diagnostic excellence and expand?patient?access, thereby?driving?precision care," said?Niccolo Stefani,?MD,?Business Leader Population Health & Clinical AI,?DeepHealth.??"These solutions transform imaging pathways,?enabling?healthcare systems to move from reactive treatment to proactive intervention?while addressing the realities of diverse European markets,?to improve patient outcomes."? 

The Industry’s Most?Comprehensive?Native?Clinical?AI Portfolio?? 
DeepHealth’s?expanded European portfolio now delivers a fully integrated, end-to-end suite of modular AI solutions,?validated?by clinical evidence and proof at scale in real-world settings. Designed to stage-shift disease through earlier detection, the portfolio enhances diagnostic consistency while driving meaningful gains in operational efficiency.? 

• Breast Suite.ⁱ?A modular solution that?integrates AI-powered detection, risk assessment,ⁱⁱ breast density?analysis?and new?mammography?analytics based on our recent acquisition of Aquila.? Aquila’s solution complements?DeepHealth’s?existing AI-powered breast imaging portfolio by adding the ability to measure,?monitor and improve image quality across technologists, sites and workflows,?thereby strengthening?clinical teams and enabling?connected, scalable care in high-volume screening environments with?the?strict compliance standards.? A?landmark?Nature Health?study validated the real-world impact of applications within the Suite,?demonstrating?a 21% increase in breast cancer detection rate among over?579,000 women.ⁱⁱⁱ??For the millions of women with dense breasts or elevated breast cancer risk, supplemental?ultrasound?is?a critical?complement to mammography — and?DeepHealth?is?now extending its Breast Suite to include?AI-powered?breast ultrasound, building on the strategic acquisition and integration of See-Mode.?Moving from detection to proactive care, Breast Suite’s?AI-powered risk assessment tool?predicts a patient’s near-term risk of developing cancer based only on a mammogram, with 2x greater accuracy than traditional risk?models.^ivv? At?ECR 2026, DeepHealth will present research^vi?showing?its AI?breast arterial calcifications (BAC)^vii?algorithm?accurately detects cardiovascular risk indicators directly from routine mammography — extending?the Breast?Suite's clinical value beyond cancer detection.? 
  
  
• Chest Suite:?Chest Suite^viii?applications?automate?pulmonary nodule detection, characterization and volumetric quantification?with?standardized reporting and longitudinal tracking?—?with the?ultimate?goal?of?stage-shifting?lung cancer.??Applications of this suite support?the?NHS?England’s?Lung Cancer?Screening?program?and?France’s CASCADE?lung cancer screening study,?validating?AI's role in?population-based lung-cancer screening. DeepHealth will present research?at ECR 2026^ixx?confirming?that AI-assisted nodule detection significantly improves radiologists' diagnostic accuracy, interobserver agreement and read efficiency?—?with consistent performance across both routine clinical and screening low-dose CT examinations.? 
  
• Neuro Suite:?Neuro Suite^xi?applications?automate?neuroimaging analysis to enable proactive neurological care,?automatically quantifying key brain structures,?including the hippocampus,?cortical?lobes?and subcortical regions, to support precise longitudinal tracking and early intervention for neurodegenerative conditions.? Awarded?“Best AI in Healthcare?2023”?at the?Italian Health System Forum,?applications within Neuro Suite demonstrated?92% sensitivity?in the early identification of hippocampal atrophy associated?with?mild?cognitive?disorders and Alzheimer’s disease.^xii??Central to?the solution?is its white matter hyperintensity (WMH) algorithm,?with?DeepHealth?research presented at?ECR 2026^xiii?demonstrating?expert-level automated quantification and consistent anatomical labeling?across?multiple FLAIR?MRI?scans —?delivering?the granular, reproducible biomarker data that?enables?meaningful risk stratification and longitudinal assessment?at scale.??  

• Prostate Suite:?Prostate Suite^xiv?integrates automated lesion detection and risk classification, intelligent gland segmentation with PSA density calculation and PI-RADS-compliant reporting into one seamless platform,?supporting?more than nine?fusion biopsy systems to?eliminate?manual data transfer and support radiologists at every critical decision point. Prostate Suite?application?has?been chosen to support TRANSFORM, the U.K.'s largest prostate cancer screening trial in a generation. At ECR, DeepHealth will present a multi-reader study,^xv which found applications of the Suite improved radiologists' area under the curve (AUC) and more than doubled interobserver agreement.
  
  
• Thyroid Suite:?Thyroid Suite^xvi?is?an AI-powered, modular solution that automates?nodule detection, characterization,?measurements?and reporting?within?existing thyroid ultrasound workflows, building on the acquisition and integration of See-Mode.??Deployment across more than 200 RadNet sites has?demonstrated transformative real-world impact: radiologists accepted AI-based measurements and characterization without correction in greater than 94% of?cases^xvii and the ability to?reduce?scan slot time by up to?30%,^xviii?thereby?expanding clinical capacity.?DeepHealth’s?ECR 2026 clinical data^xix?reinforces this impact, showing that AI?assistance?significantly reduced interpretation time while improving radiologist accuracy,?agreement?and consistency in thyroid nodule characterization.? 
  
  
• AI?Studio:?Supporting its integrated Population Health suites,?DeepHealth’s?AI Studio Suite provides a unified platform to accelerate enterprise-wide AI adoption with confidence.  AI Studio adds more than 140 AI algorithms from over 75 ecosystem partners — alongside?DeepHealth’s?own clinical AI applications — and seamlessly orchestrates them within the clinical workflow, including the worklist, viewer, reporting modules and workflow engine. The platform enhances automation, streamlines deployment and elevates the viewing and reporting experience.  In parallel, AI Studio delivers comprehensive governance capabilities, including AI validation, continuous monitoring and drift management in production, ensuring consistent performance and the safe, reliable scaling of AI across the healthcare enterprise.? 
  
  

“DeepHealth's?unified platform has fundamentally changed how we serve our patients,” commented the medical leadership of Emicenter Diagnostic Center in Italy.??“From prostate and lung cancer screening to the assessment of neurodegenerative disease, we now have one cohesive, AI-powered ecosystem that gives our radiologists the clinical confidence to detect disease earlier and the workflow efficiency to do it at?scale.”? 

Delivering the Next Era of AI-Powered Health Informatics?? 
With the integration of Gleamer’s?solutions?into?DeepHealth’s?established clinical AI suites, the company now offers the most comprehensive radiology AI portfolio in the market adding a significant portfolio in musculoskeletal and X-ray imaging. The combined solutions support screening, detection, interpretation and follow-up across many of the most prevalent cancers, as well as neurodegenerative and musculoskeletal conditions, including trauma and chronic disease.? 

DeepHealth's?expanded?clinical AI?portfolio,^xx including?its?Diagnostic Suite™?cloud-first enterprise image management and interpretation solution, and?the?newly CE-marked?TechLive™ multimodality?vendor-agnostic?remote image management?solution,?will be?showcased?at ECR 2026 at Booth No. 506 | Hall X5.??For more information?or?to schedule a demonstration, visit?www.deephealth.com/ECR.? 
? 
About?DeepHealth?? 
DeepHealth?is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment.?DeepHealth?provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging.?DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, musculoskeletal, neuro,?prostate?and thyroid health.?At the heart of?DeepHealth’s?portfolio is a cloud-native operating system –?DeepHealth?OS – that unifies data across the clinical and operational workflow.?Thousands of imaging centers and radiology departments around the world use?DeepHealth?solutions to enable earlier, more?reliable?and more efficient disease detection, including in large-scale cancer screening programs.?DeepHealth’s?human-centered, intuitive technology aims to push the boundaries of?what’s?possible in healthcare. Learn more at?deephealth.com.? 
? 
About RadNet, Inc.?? 
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.?RadNet has a network of owned and/or operated outpatient imaging centers.?RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Indiana, Maryland, New Jersey,?New York, Texas and Virginia.?In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the?DeepHealth?brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally.?Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members.?Learn more at?radnet.com.? 
? 
Forward-Looking Statements? 
This communication?contains?certain “forward-looking statements” within the meaning of the safe?harbor?provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.??Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods.??Examples of forward-looking statements include statements?regarding?our technology’s ability to?address the compounding challenges facing healthcare systems, including workforce constraints, rising imaging volumes and the need for consistent, high-quality diagnostic pathways;?discussions?regarding?our product features;?and statements?regarding?our recent acquisitions.??Actual results could differ materially from those currently?anticipated?due to?a number of?risks and uncertainties, many of which are beyond RadNet’s control.? 
? 
Forward-looking statements are neither historical facts nor assurances of future performance.??Instead, they are based only on management’s current beliefs,?expectations?and assumptions?regarding?the future of RadNet’s business,?future plans?and strategies, projections,?anticipated events and trends, the economy and other future conditions.?Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to?predict?and many of which are outside of RadNet’s control.?RadNet’s actual results and financial?condition?may differ materially from those indicated in the forward-looking statements?as a result of?various factors.?Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will?actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet.?Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition.?Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes, and other risks and uncertainties described in the “Risk Factors,” “Management’s Discussion and Analysis,” and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.??The foregoing review of?important factors?should not be construed as exhaustive and?should be read in conjunction with the other cautionary statements that are included elsewhere.??Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.? 
? 
Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent.?All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.? 
? 
DeepHealth?Media Contact? 
Andra Axente? 
Director of Communications? 
+31614440971? 
andra.axente@deephealth.com? 
? 
RadNet Media Contacts?? 
Jane Mazur?? 
Senior?Vice?President, Corporate Communications? 
+1 585-355-5978?? 
jane.mazur@radnet.com?? 
? 
Mark Stolper? 
Executive Vice President and Chief Financial Officer? 
+1 310-445-2800? 

? 
References? 

ⁱ Breast Suite comprises multiple applications including ProFound Pro, Breast Density, Safeguard Review, Risk Assessment, BAC and DeepHealth Viewer, Mammography Insights and Breast Ultrasound. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Mammography Insights is manufactured by Aquila, Inc. and distributed by DeepHealth, Inc. Breast Ultrasound is manufactured by See-Mode, Inc. and distributed by DeepHealth, Inc. Any claims made about Breast Suite may reference claims associated with its individual components.
ⁱⁱ CE marked for the EU market. Not yet cleared for use in the US.
ⁱⁱⁱ Louis et al. “Equitable impact of an AI-driven breast cancer screening workflow in real-world US-wide deployment.” Nature Health. Nov 2025.
^iv Eriksson et al. “A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care.” Science Translational Medicine. May 2022.
^v Eriksson et al. “Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening.” Radiology. Sep 2020.
^vi Hasegawa, A., Pike, J., Gkanatsios, N., Go, J., Everitt, B., Ge, J., Ren, Y., Ng, A., Kim, J., & Haslam, B., “AI assistant for detection and localization of breast arterial calcifications on FFDM and DBT mammography with potential cardiovascular risk implications,” European Congress of Radiology (ECR) 2026. Poster presentation. March 2026.
^vii In development.
^viii Chest Suite comprises multiple applications, including Veye Lung Nodules, Veye Reporting, DeepHealth Lung AI, DeepHealth Viewer and HealthCCSng.  Veye Lung Nodules and Veye Reporting are manufactured by Aidence B.V. and distributed by DeepHealth, Inc.  Neither Veye Lung Nodules nor Veye Reporting are FDA cleared for distribution in the U.S.  DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. in the U.S.  HealthCCSng is manufactured by Nanox AI, Ltd. and distributed by DeepHealth, Inc.  DeepHealth Lung AI is 510(k) pending.  Any claims made about Chest Suite may reference claims associated with its individual components. Not all products and functions are available in all markets.
^ix Kim, J., Engbersen, M., Mollink, J., Poirot, M., Kurilova, I., Everitt, B., Hasegawa, A., and Haslam, B., “AI-assisted lung nodule detection on computed tomography: effects on diagnostic accuracy, consistency, and efficiency,” European Congress of Radiology (ECR) 2026. Poster presentation. March 2026.
^x Wakelin, E., Mollink, J., Koulakis, M., Engbersen, M., & Haslam, B., “Evaluation of AI Detection of Lung Nodules in Routine Chest CTs Compared to Lung Cancer Screening CTs,” European Congress of Radiology (ECR) 2026. Poster presentation. March 2026.
^xi Neuro Suite comprises multiple applications, including Brain Health, Brain Age and DeepHealth Viewer.  DeepHealth Viewer is manufactured by eRAD, inc. and distributed by DeepHealth.  Any claims made about Neuro Suite may reference claims associated with its individual components.  Not all products and functions are available in all markets.
^xii Preliminary data from the observational study conducted at ASL Roma 2 on 226 geriatric patients starting from February 2023 to date, to investigate early diagnosis of dementia with the use of neuropsychological tests and AI-powered (DeepHealth ND) MRI automated evaluation of brain volumetry.
^xiii Moeskops, P., Mulder, L., Wakelin, E., Ng, A., Kim, J., & Haslam, B., “Automated quantification and localization of white matter hyperintensities in FLAIR MRI to support disease risk stratification and longitudinal assessment,” European Congress of Radiology (ECR) 2026. Poster presentation. March 2026.
^xiv DeepHealth Prostate Suite comprises multiple applications including Quantib Prostate, DeepHealth Prostate AI and DeepHealth Viewer. Quantib Prostate is Manufactured by Quantib BV and distributed by DeepHealth, Inc, in the US. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. DeepHealth Prostate AI is FDA 510(k) pending Any claims made about Prostate Suite may reference claims associated with its individual components.
^xv Everitt, B., Fortunati, V., Kim, J., Tol, J., Ko, A., Kolpa, G., Leufkens, F., & Haslam, B., “Impact of an integrated AI platform on prostate MRI interpretation: a multi-reader study,” European Congress of Radiology (ECR) 2026. Poster presentation. March 2026.
^xvi DeepHealth Thyroid Suite comprises multiple applications, including DeepHealth Viewer and DeepHealth Thyroid AI.  DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth.  DeepHealth Thyroid AI is manufactured as See-Mode Augmented Reporting Tool, Thyroid (SMART-T) by See-Mode and distributed by DeepHealth Inc. Any claims made about Thyroid Suite may reference claims associated with its individual components.  Not all products and functions are available in all markets.
^xvii Results are based on data from 240+ RadNet sites and 22,000 thyroid studies [Data on File].
^xviii Demonstrated up to a 30% reduction in scan slot time. Results from early solution deployment on RadNet sites [Data on File].
^xix Monajemi, S., Louis, L. D., Ng, A., Engin, M., Surendrakumar, S., Parkitny, S., Vo, J., Mohammadzadeh, M., & Haslam, B., “AI assistant improves interpretation efficiency, consistency and accuracy for thyroid ultrasound,” European Congress of Radiology (ECR) 2026. Poster presentation. March 2026.
^xx Not all products are regulatory cleared for use in all markets. Regulatory clearance varies by region and product. Please refer to www.deephealth.com or contact our regulatory affairs team for more information on the specific clearances applicable in your market.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c259eede-a9aa-4878-b943-09d8eb96ab2c